Find a Clinical Trial
Filter
A Study of Sargramostim Plus Pembrolizumab With or Without Pemetrexed in Patients With Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy
Non-small cell lung cancer
All genders
18+
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Division of Thoracic Surgery
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
Diffuse large B-cell lymphoma
All genders
75+
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin (VOLGA)
Bladder cancer
All genders
18+
Recruiting now
Department of Medicine, Cancer Center
Perioperative versus adjuvant chemotherapy for pancreatic cancer
Pancreatic cancer
All genders
18+
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center
The ImmuneSense Study
Glioblastoma
All genders
18-70
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center
To Evaluate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
Small cell lung cancer
All genders
18+
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy
All genders
18+
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Lymphomas (adult)
All genders
18+
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center
Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients
Cancer
All genders
18+
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center
A clinical trial investigating BNT113 in combination with pembrolizumab versus pembrolizumab alone for patients with a form of head and neck cancer positive for human papilloma virus 16 and expressing the protein PD-L1
Head and neck cancer
All genders
18+
Recruiting now
Cancer Center